Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Vaccines

Free Subscription Articles published in PLoS Med Retrieve available abstracts of 28 articles: HTML format

Single Articles

March 2026
1. ABDEL-QADIR H, Bhatt HA, Swayze S, Paterson M, et al
   Association between COVID-19 vaccination and sudden death in apparently healthy younger individuals: A population-based case-control study.
   PLoS Med. 2026;23:e1004924.
   PubMed     Abstract available
   
   
   
2. GRAY EJ, Cooper LV, Gonzalez AR, Mach O, et al
   Estimating population immunity against serotype-two poliomyelitis from the inactivated polio vaccine in routine immunization across 112 countries: A modelling study.
   PLoS Med. 2026;23:e1004952.
   PubMed     Abstract available
   
   
   February 2026
3. TANVIR H, Clark RA, Sumner T, Horton KC, et al
   Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study.
   PLoS Med. 2026;23:e1004595.
   PubMed     Abstract available
   
   
   
4. CARVALHO N, Watts E, Oliver VL, Clark A, et al
   Evaluation of rotavirus, pneumococcal conjugate and human papillomavirus vaccination in four Pacific island countries: A cost-effectiveness modelling study.
   PLoS Med. 2026;23:e1004604.
   PubMed     Abstract available
   
   
   January 2026
5. STANTON TD, Keegan SP, Abdulahi JA, Amulele AV, et al
   Distribution of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and South Asia: A meta-analysis of genome-predicted serotype prevalence to inform potential vaccine coverage.
   PLoS Med. 2026;23:e1004879.
   PubMed     Abstract available
   
   
   
6. MONOI A, Endo A, Procter SR, Leuba SI, et al
   The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.
   PLoS Med. 2026;23:e1004625.
   PubMed     Abstract available
   
   
   December 2025
7. GOTTLIEB SL, Rees H, Peters RPH
   Vaccines to prevent bacterial sexually transmitted infections: Promise, progress, and public health potential.
   PLoS Med. 2025;22:e1004849.
   PubMed     Abstract available
   
   
   November 2025
8. JIAO B, Sato R, Mak J, Patenaude B, et al
   Financial risk protection from vaccines in 52 Gavi-eligible low- and middle-income countries: A modeling study.
   PLoS Med. 2025;22:e1004764.
   PubMed     Abstract available
   
   
   October 2025
9. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
   Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
   PLoS Med. 2025;22:e1004499.
   PubMed     Abstract available
   
   
   
10. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
    Correction: Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
    PLoS Med. 2025;22:e1004789.
    PubMed     Abstract available
    
    
    September 2025
11. MANDOLO J, Mulira L, Moyo M, Mvula M, et al
    Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study.
    PLoS Med. 2025;22:e1004734.
    PubMed     Abstract available
    
    
    
12. JIN S, Asakura TR, Murayama H, Niyukuri D, et al
    Vaccination strategies to achieve outbreak control for MPXV Clade I with a one-time mass campaign in sub-Saharan Africa: A scenario-based modelling study.
    PLoS Med. 2025;22:e1004726.
    PubMed     Abstract available
    
    
    July 2025
13. LI J, Li Y, Qin C, He Y, et al
    Effect of a pay-it-forward strategy on reducing HPV vaccine delay and increasing uptake among 15- to 18-year-old girls in China: A randomized controlled trial.
    PLoS Med. 2025;22:e1004535.
    PubMed     Abstract available
    
    
    June 2025
14. GOODFELLOW L, Procter SR, Koltai M, Waterlow NR, et al
    The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis.
    PLoS Med. 2025;22:e1004655.
    PubMed     Abstract available
    
    
    
15. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
    Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
    PLoS Med. 2025;22:e1004631.
    PubMed     Abstract available
    
    
    April 2025
16. 
    Correction: Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004605.
    PubMed     Abstract available
    
    
    February 2025
17. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004521.
    PubMed     Abstract available
    
    
    
18. INGABIRE R, Nyombayire J, Mazzei A, Mazarati JB, et al
    Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
    PLoS Med. 2025;22:e1004508.
    PubMed     Abstract available
    
    
    
19. GRAIS RF, Neuzil KM, Rees H, Toscano CM, et al
    Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy.
    PLoS Med. 2025;22:e1004530.
    PubMed     Abstract available
    
    
    
20. GUTTIERES D, Diepvens C, Grais RF, Kiarie J, et al
    Charting a novel path towards Ebola virus disease preparedness: Considerations for preventive vaccination.
    PLoS Med. 2025;22:e1004543.
    PubMed     Abstract available
    
    
    January 2025
21. SEIDLEIN LV
    Roll out and prospects of the malaria vaccine R21/Matrix-M.
    PLoS Med. 2025;22:e1004515.
    PubMed     Abstract available
    
    
    
22. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
    Correction: Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
    PLoS Med. 2025;22:e1004573.
    PubMed     Abstract available
    
    
    October 2024
23. MUNDAY JD, Atkins KE, Klinkenberg D, Meurs M, et al
    Estimating the risk and spatial spread of measles in populations with high MMR uptake: Using school-household networks to understand the 2013 to 2014 outbreak in the Netherlands.
    PLoS Med. 2024;21:e1004466.
    PubMed     Abstract available
    
    
    September 2024
24. INIZAN C, Courtot A, Sturmach C, Griffon AF, et al
    Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    PLoS Med. 2024;21:e1004397.
    PubMed     Abstract available
    
    
    June 2024
25. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    PubMed     Abstract available
    
    
    
26. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    PLoS Med. 2024;21:e1004375.
    PubMed     Abstract available
    
    
    April 2024
27. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    PubMed     Abstract available
    
    
    March 2024
28. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum